Multiple Myeloma Research Foundation (MMRF) Welcomes Joel Marcus to Its Board of Directors

Tools

MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) WELCOMES JOEL MARCUS TO ITS BOARD OF DIRECTORS

The Multiple Myeloma Research Foundation (MMRF) today announced that Joel S. Marcus has joined its Board of Directors. Mr. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (ARE: NYSE), Alexandria Venture Investments, and the Alexandria Summit™.

"We are honored to welcome Joel Marcus to the MMRF Board of Directors," said Kathy Giusti, Founder and CEO of the MMRF and a multiple myeloma patient. "Joel's exceptional business acumen and appreciation for the need for innovation in healthcare, as demonstrated through the groundbreaking Alexandria Summit, will undoubtedly bolster our efforts to accelerate new treatments and a cure for multiple myeloma which, leveraged, could also benefit other cancers."

Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994 and Alexandria Venture Investments in 1996. In 2011, he founded the Alexandria Summit, an annual meeting that brings together the world's foremost visionaries from the pharmaceutical and biotechnology industries, academia, the non-profit sector, government, and philanthropic organizations to tackle pressing healthcare challenges.

Prior to this, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. Previously, he served as General Counsel and Secretary of Kirin-Amgen, Inc. and was a practicing certified public accountant and tax manager with Arthur Young & Co.

Mr. Marcus currently serves on the boards of the Accelerator Corporation, an organization he co-founded, the Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., and the Partnership for New York City.

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 41 percent, one of the lowest of all cancers. In 2013, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $225 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator's coveted four four-star rating for nine consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

Contacts

Media:
Anne Quinn Young, MMRF
203-536-8691
QuinnYoungA@themmrf.org